Myasthenia gravis
Drug research and approvals for myasthenia gravis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 89 studies of myasthenia gravis are recruiting on ClinicalTrials.gov, Health Canada has authorized 59 drug trials for it since 2013, FDA has 13 approved and 27 open orphan designations naming it, and the EU has 5 authorised medicines for it.
- Recruiting worldwide: 89
- Trials authorized in Canada: 59
- FDA orphan approvals: 13
- EU medicines: 5
- Feasibility of Remote Monitoring of Patients With Myasthenia GravisNCT07787247 · Not reported · George Washington University · starts Aug 19, 2026
- AXIS MG Patient RegistryNCT07761026 · Not reported · Autoimmune Neurology Alliance · starts Mar 19, 2026
- PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia GravisNCT07717281 · Not reported · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts Jun 4, 2026
- ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in…NCT07673627 · Phase 2 · argenx · starts Jul 10, 2026
- A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod…NCT07673744 · Phase 2 · TG Therapeutics, Inc. · starts Nov 1, 2026
- Cohort Study on Neuroimmune Diseases in the Reproductive AgeNCT07653984 · Not reported · Third Affiliated Hospital, Sun Yat-Sen University · starts Apr 21, 2024
- A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)NCT07647510 · Phase 3 · Dianthus Therapeutics · starts Jun 29, 2026
- A Phase II Study of SHR-2173 Injection in Patients With Myasthenia GravisNCT07622342 · Phase 2 · Guangdong Hengrui Pharmaceutical Co., Ltd · starts Aug 28, 2026
- Study of Aritinercept in Patients With Generalized Myasthenia GravisNCT07596901 · Phase 1 / Phase 2 · Aurinia Pharmaceuticals Inc. · starts Apr 22, 2026
Approved 7
- Efgartigimod alfaIgG receptor FcRn large subunit p51 antagonist
- RozanolixizumabIgG receptor FcRn large subunit p51 inhibitor
- PyridostigmineAcetylcholinesterase inhibitor
- AmifampridineLambert-eaton myasthenic syndrome · Voltage-gated potassium channel blocker
- NeostigmineAcetylcholinesterase inhibitor
- PralidoximeAcetylcholinesterase activator
- GuanidineLambert-eaton myasthenic syndrome · Voltage-gated potassium channel blocker
Phase 3 12 of 18
- ZilucoplanComplement C5 inhibitor
- RituximabB-lymphocyte antigen CD20 binding agent
- BatoclimabIgG receptor FcRn large subunit p51 inhibitor
- EculizumabComplement C5 inhibitor
- NipocalimabIgG receptor FcRn large subunit p51 antagonist
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- PrednisoneGlucocorticoid receptor agonist
- Human immunoglobulin gReplacement therapy, immunomodulatory effects
- Telitacicept
- AzathioprineAmidophosphoribosyltransferase inhibitor
- LeflunomideDihydroorotate dehydrogenase inhibitor
Phase 2 10
- TocilizumabInterleukin-6 receptor alpha subunit inhibitor
- CytarabineDNA inhibitor
- MethotrexateDihydrofolate reductase inhibitor
- CarmustineGlutathione reductase inhibitor
- ApraclonidineAdrenergic receptor alpha-2 agonist
- TirasemtivFast skeletal troponin complex activator
- IscalimabTumor necrosis factor receptor superfamily member 5 inhibitor
- MezagitamabLymphocyte differentiation antigen CD38 binding agent
- OrilanolimabIgG receptor FcRn large subunit p51 antagonist
- Vemircopan
Phase 1 or earlier 6
- 2-mercaptoethanesulfonic acid
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- CyclophosphamideDNA inhibitor
- Oxaloacetate
- TofacitinibJanus Kinase (JAK) inhibitor
- AbataceptT-lymphocyte activation antigen CD86 inhibitor
How its trials ended
235 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 45 whose ending is known, 49% met their primary endpoint, 13% missed it and 38% stopped early.
- Ongoing10344%
- Completed, result not reported6226%
- Status unknown2511%
- Met its primary endpoint229%
- Stopped: other or unclear83%
- Missed its primary endpoint63%
- Stopped: sponsor or business decision52%
- Stopped: enrollment or feasibility31%
- Stopped: lack of efficacy1<1%
| Oct 30, 2026 | A phase 3, randomized, double-masked, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, pharmacokinetics,…Klygefa (gefurulimab (ALXN1720)) | AstraZeneca Pharmaceuticals | Pending |
| Jul 29, 2026 | A phase 3 global, multicenter, randomized, double-blind, placebo-controlled study to demonstrate the efficacy, safety, and tolerability of claseprubart…Claseprubart (DNTH103) | Dianthus Therapeutics | Pending |
| May 26, 2026 | A phase 3, open-label extension study to evaluate the long-term safety and efficacy of rozanolixizumab in adult participants with ocular myasthenia gravisRystiggo (UCB7665) | UCB | Ongoing |
| Apr 28, 2026 | A double-blind, randomized, placebo-controlled study to investigate the safety and efficacy of aritinercept, a dual baff/april inhibitor, in patients with…Aritinercept (AUR200) | Aurinia Pharmaceuticals | Ongoing |
| Apr 8, 2026 | A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rozanolixizumab in adult participants with ocular…Rozanolixizumab (UCB7665) | UCB | Ongoing |
| Dec 2, 2025 | A phase 1b/2, multicenter, randomized, double-blind, placebo-controlled study to investigate a) the safety, tolerability, pharmacokinetics, and…IM-101 | Immunabs Inc. | Pending |
| Nov 13, 2025 | A phase 2 open-label multicenter study to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of inebilizumab in children from 2 years to…Uplizna | Amgen | Closed |
| Aug 1, 2025 | A randomized, double-blind, placebo-controlled phase 3 trial of descartes-08 in patients with acetylcholine receptor antibody-positive generalized myasthenia…Descartes-08 | Cartesian Therapeutics | Ongoing |
| Jul 18, 2025 | A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized…Iptacopan (LNP063) | Novartis Pharmaceuticals | Closed |
| May 8, 2025 | A phase 3, randomized, double-blind, placebo-controlled study with an open-label extension period to evaluate the efficacy and safety of telitacicept in…Telitacicept (RC18, RC18-L) | Vor Biopharma | Closed |
| Nov 13, 2026 | KlygefaTreatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive | Alexion Pharmaceuticals, Inc. | Approved |
| May 8, 2026 | Vyvgart HytruloTreatment of adult patients with generalized myasthenia gravis (gMG) | argenx BV | Approved |
| May 8, 2026 | VyvgartTreatment of adult patients with generalized myasthenia gravis (gMG) | argenx BV | Approved |
| Dec 11, 2025 | UpliznaTreatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific… | Horizon Therapeutics Ireland Designated Activity Company (a subsidiary of Amgen Inc.) | Approved |
| Apr 29, 2025 | ImaavyTreatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine… | Janssen Research & Development, LLC | Approved |
| Apr 10, 2025 | Vyvgart HytruloTreatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive | argenx BV | Approved |
| Feb 28, 2025 | SolirisTreatment of generalized myasthenia gravis (gMG) in adult and pediatric patients six years of age and older who are anti-acetylcholine… | Alexion Pharmaceuticals, Inc. | Approved |
| Oct 17, 2023 | ZilbrysqTreatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive | UCB, Inc. | Approved |
| Jun 26, 2023 | RystiggoTreatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific… | UCB, Inc. | Approved |
| Jun 20, 2023 | Vyvgart HytruloTreatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive | argenx BV | Approved |
| Apr 27, 2022 | UltomirisTreatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive | Alexion Pharmaceuticals, Inc. | Approved |
| Dec 17, 2021 | VyvgartTreatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive | argenx BV | Approved |
| Oct 23, 2017 | SolirisFor the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive | Alexion Pharmaceuticals, Inc. | Approved |
| May 1, 2026 | ClaseprubartTreatment of myasthenia gravis | Dianthus Therapeutics, Inc. | Designated |
| Feb 2, 2026 | PovetaciceptTreatment of generalized myasthenia gravis (gMG) | Vertex Pharmaceuticals Incorporated | Designated |
| Nov 28, 2025 | ImaavyNipocalimab | Janssen Cilag International NV | EMA ↗ |
| Jan 5, 2024 | RystiggoRozanolixizumab · orphan | UCB Pharma | EMA ↗ |
| Dec 1, 2023 | ZilbrysqZilucoplan | UCB Pharma S.A. | EMA ↗ |
| Aug 10, 2022 | VyvgartEfgartigimod alfa · orphan | Argenx | EMA ↗ |
| May 19, 2022 | Amifampridine SERBAmifampridine · generic | Serb SA | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA